A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD

Trial Profile

A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Fasoracetam (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Acronyms SAGA
  • Sponsors Aevi Genomic Medicine
  • Most Recent Events

    • 20 Apr 2017 Updated responder data from a subset of genomically identified patients, published in an Aevi Genomic Medicine media release.
    • 12 Apr 2017 According to an Aevi Genomic Medicine media release, results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6th World Congress on ADHD (Attention Deficit Hyperactivity Disorder).
    • 20 Mar 2017 According to an Aevi Genomic Medicine media release, Robert L. Findling is a Principal Investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top